Category: Uncategorized
-
Reimagining Cancer Treatment: The 2026 Tang Prize Laureates in Biopharmaceutical Science
The ACTO Times, Editorial Office The 2026 Tang Prize in Biopharmaceutical Science has been awarded jointly to Steven A. Rosenberg, Michel Sadelain, and Carl H. June for their groundbreaking contributions to the development of cellular immunotherapy, a revolutionary approach that enables a patient’s own immune system to recognize and destroy cancer [1,2]. Established in Taiwan in…
-
South Korea’s Regulatory Architecture for Cell and Gene Therapies: Linking Clinical Research, Regulated Treatment, and Product Authorization
The ACTO Times, Editorial Office Abstract South Korea has established a distinctive regulatory architecture for cell and gene therapies that links advanced regenerative medicine, institution-based clinical research, medicinal-product development, and long-term safety oversight. The central framework was introduced through the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products,…
-
China’s Evolving Regulatory Framework for Cell and Gene Therapies: From Dual-Track Oversight to a New Legal Phase
The ACTO Times, Editorial Office Abstract China has developed one of the world’s most active cell and gene therapy research environments, accompanied by a regulatory system that has evolved rapidly over the past decade. The framework has often been described as “dual-track,” comprising a drug-product pathway administered by the National Medical Products Administration and a…
-
ACTO 2026 Distinguished Speakers
ACTO & Indonesia National Leadership Prof. Akihiro Shimosaka, PhD Chairperson, Asian Cellular Therapy OrganizationProf. Akihiro Shimosaka is Chairperson of the Asian Cellular Therapy Organization and Director of the Research and Development Division at the Research Foundation for Community Medicine in Japan. He has extensive international experience in biotechnology research, product development and regulatory affairs, with…
-
Greeting from Editor-in Chief
THE ACTO TIMES: 2026 Summer Edition Dear Readers and Friends of The ACTO Times, It is my great pleasure to welcome you to the 2026 Summer Edition of The ACTO Times. As we enter the summer season and prepare for the upcoming 2026 ACTO-ASPI Annual Meeting, to be held on August 26–28 in Jakarta, Indonesia,…
-
GREETINGS FROM THE ACTO CHAIRPERSON
The ACTO times: 2026 Summer edition Dear ACTO members and readers, It is our great pleasure to distribute ACTO Times 2026 Summer Version today. We are grateful to Prof. Huang and the ACTO Times editorial office team members who made it possible again. We are expecting the 17th ACTO Annual Meeting in Jakarta, supported by Indonesia Ministry…
-
Overcoming manufacturing bottlenecks in cell and gene therapy: The emergence of the intelligent development and manufacturing organization (IDMO) model in Asia
Yu-Hsiang Chang, Ph.D.Chief Executive Officer (CEO), Locus Cell Co., Ltd. Abstract The clinical efficacy of Chimeric Antigen Receptor T-cell (CAR-T) therapies has irrevocably transformed the landscape of oncology and personalized medicine. Despite these groundbreaking clinical successes, the broad accessibility of these advanced therapies is severely limited by traditional manufacturing paradigms. High production costs, reliance on…
-
From Formosa to the world: leading the new era of regenerative medicine and cellular therapy in Taiwan
Dr. Chen-Chie Wang, MD., Ph.D.President of Formosa Association of Regenerative Medicine (FARM)Director of Department of Orthopedic Surgery, Taipei Tzu Chi Hospital, New Taipei City, TaiwanDepartment of Orthopedics, School of Medicine, Hualien Tzu Chi University, Hualien, Taiwan Regenerative medicine has rapidly evolved from experimental concepts into a transformative force in standard clinical care, ushering in a new…
-
Taiwan Association for Cellular Therapy (TACT)
April 29, 2026 The Taiwan Association for Cellular Therapy (TACT; https://www.celltherapy.org.tw/) was founded in 2014 with the mission of promoting cross-sector collaboration among industry, government, academia, medical institutions, and research communities in the field of cellular therapy. The Association is dedicated to advancing cell therapy science, technology, education, clinical translation, industrial development, and the establishment and refinement…
-
Therapeutic Potentials of Induced Pluripotent and Mesenchymal Stem Cell-Derived Exosomes
Vijetha Karen Kitchley, M.Sc.Editorial Office, The ACTO TimesInternational PhD Program in Cell Therapy & Regenerative Medicine, Taipei Medical University, Taiwan Introduction Mesenchymal stem cells (MSCs) have long been at the forefront of regenerative medicine due to their multipotency and immunomodulatory properties[1, 2]. However, direct stem cell transplantation is often limited by challenges such as donor-to-donor…
